Created with adult peripheral blood mononuclear cells, engrafting quickly and enabling short-term studies requiring mature human T cells.
Key features:
- Strong T cell engraftment, including effector and memory T cells.
- NSG™ supports greater engraftment of human PBMCs than other currently available strains (King et al. 2008).
- Enables immediate short-term experiments with higher throughput.
- Graft-versus-host disease develops within 4-5 weeks.
PBMC humanization process
Female NSG™ mice are injected with human peripheral blood mononuclear cells (hu-PBMCs). Mice can be shipped to the customer within days of engraftment. Engraftment (principally T cells) can increase over time, but it is limited by the development of graft-versus-host disease.
Availability
Study-ready cohorts of hu-PBMC humanized mice are provided upon request, either for shipment to your institution or for enrollment in customized drug efficacy studies executed by our In Vivo Services scientists.
Licensing requirements for humanized mice
We distribute NSG™ mice under an agreement with the NIH. NSG™ mice are available to non-profit research institutions under an MTA. Companies and for profit entities require a license prior to shipping. Many companies already have a license that includes engrafted NSG™ mice. To confirm that your company is covered or for new license inquiries, please contact:
Peter Wells
Director, Technology Transfer
The Jackson Laboratory
Phone: 207-288-6883
Email: Peter.Wells@jax.org